Opus Genetics FY2026 EPS Cut by Brookline Capital Markets

Posted by Geri Gentry on Jun 12th, 2026

Opus Genetics, Inc. (NASDAQ:IRD – Free Report) – Equities researchers at Brookline Capital Markets decreased their FY2026 earnings per share (EPS) estimates for Opus Genetics in a research note issued to investors on Wednesday, June 10th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn ($1.31) per share for the year, down from their previous forecast of ($0.57). The consensus estimate for Opus Genetics’ current full-year earnings is ($0.97) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ Q4 2026 earnings at ($0.06) EPS and FY2027 earnings at ($0.77) EPS.

Opus Genetics (NASDAQ:IRD – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 338.88%. The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $2.93 million.

Several other research firms have also recently issued reports on IRD. Zacks Research raised shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a report on Wednesday. Chardan Capital raised their target price on shares of Opus Genetics from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. Wall Street Zen lowered shares of Opus Genetics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citizens Jmp cut their target price on shares of Opus Genetics from $12.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Finally, Guggenheim assumed coverage on Opus Genetics in a research note on Thursday, June 4th. They set a “buy” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Get Our Latest Report on Opus Genetics

Opus Genetics Stock Performance

Shares of IRD opened at $3.91 on Friday. Opus Genetics has a fifty-two week low of $0.90 and a fifty-two week high of $5.81. The company has a market capitalization of $322.85 million, a price-to-earnings ratio of -2.94 and a beta of 0.56. The firm has a 50-day simple moving average of $4.80 and a 200-day simple moving average of $3.65.

Institutional Trading of Opus Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP lifted its holdings in shares of Opus Genetics by 169.6% during the 3rd quarter. Two Sigma Investments LP now owns 108,338 shares of the company’s stock worth $179,000 after acquiring an additional 68,148 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Opus Genetics during the 4th quarter valued at about $177,000. ADAR1 Capital Management LLC bought a new position in shares of Opus Genetics in the fourth quarter worth about $80,000. Johnson Investment Counsel Inc. bought a new position in shares of Opus Genetics in the fourth quarter worth about $40,000. Finally, Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics in the fourth quarter worth about $25,000. 14.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, President Benjamin R. Yerxa sold 7,470 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.24, for a total transaction of $39,142.80. Following the completion of the sale, the president directly owned 711,535 shares in the company, valued at approximately $3,728,443.40. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the completion of the sale, the director owned 3,792,171 shares of the company’s stock, valued at approximately $16,495,943.85. This trade represents a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,773,395 shares of company stock valued at $7,777,278 in the last ninety days. 11.70% of the stock is owned by company insiders.

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.